Sensex
73,983.18 profit arw 64.42 (0.09%)
Nifty
23,214.95 profit arw -27.15 (-0.12%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

BSE Announcement Details

As on : 10-Jun-2026
Concord Biotech receives USFDA approval for Tofacitinib Tablets
 <P>Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA).</P> <P>According to market estimates, the U.S. market for Tofacitinib Tablets both strengths put together is approximately US$ 500 million. The approval positions the Company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets.</P>

INDIAN INDICES

Sensex

73,983.18 64.42 (0.09%)

Nifty

23,214.95 -27.15 (-0.12%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

24,407.97 -157.94(-0.64%)